E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Participants will be diagnosed with panic disorder, a severe form of anxiety that is characterised by the ocurrence of intense panic attacks, without an apparent external reason. |
|
E.1.1.2 | Therapeutic area | Psychiatry and Psychology [F] - Psychological processes [F02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10068300 |
E.1.2 | Term | Panic attacks and disorders |
E.1.2 | System Organ Class | 100000004873 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Does the combination of a single-session of cognitive-behaviour therapy (CBT) with the cognitive enhancer d-cycloserine (compared to placebo) lead to greater reduction in threat bias (computerised behavioural reaction tasks) on the day after treatment? |
|
E.2.2 | Secondary objectives of the trial |
Is such an increased change in threat bias underpinned by stronger alterations in responsivity in the fear circuit of the brain (fMRI) on the day after treatment? Does CBT plus d-cycloserine (versus placebo) lead to greater symptom improvement on the day after treatment and at follow-ups? Does CBT plus d-cycloserine (versus placebo) lead to greater stress resistance on the day after treatment and at follow-ups (stress test + VAS)? Are threat bias and/or brain responsivity on the day after treatment predictive of symptom changes during 1-month and 6-month follow-up? |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Diagnosed with DSM-IV panic disorder • At least moderate avoidance of agoraphobic situations (”yes” response to at least 3 situations listed under “(2) Avoidance – Do you avoid or feel very uncomfortable in …” in the Structured Panic Assessment Interview (Clark, 1989)) • Participant is willing and able to give informed consent for participation in the study and to comply with all study requirements. • Male or Female, aged 18 years or above.
|
|
E.4 | Principal exclusion criteria |
• Female participant who is pregnant, breast-feeding, or planning pregnancy • CNS-active medication during the last 6 weeks • Exposure-based psychological treatment for panic disorder and agoraphobia during the last 3 months • Lifetime history of psychosis, bipolar disorder, alcohol, medication or drug abuse or dependence; current primary depressive disorder • Lifetime history of epilepsy or other significant disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant’s ability to participate in the study. • Insufficient English skills • Patient not able to refrain from benzodiazepines 48hrs before treatment and testing sessions • Any other significant disease or disorder or circumstance, which, in the opinion of the investigator, may either put the participant at risk or may influence the results of the study or the participant’s ability to participate in the study.
Participants with contraindication to MRI scanning (e.g. pacemaker, metal implant, left-handedness) will be included in the study but will not undergo the MRI scan study component.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Threat bias reaction time scores derived from computerised behavioural reaction tasks |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
This end point will be assessed at baseline (Visit 2) and on the day after treatment (Visit 3). |
|
E.5.2 | Secondary end point(s) |
a) responsivity in the fear circuit of the brain b) self-report symptom severity (Beck Depression Inventory, State and Trait form of the State-Trait Anxiety Inventory, Agoraphobic Cognitions Questionnaire, Body Sensations Questionnaire, Mobility Inventory, Panic Attack Scale) c) clinician-rated symptom severity (Panic Disorder Severity Scale - Clinician) d) anxiety ratings during a stress test (VAS)
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
a) functional and structural MRI will be measured on the day after treatment (Testing Visit/ Visit 3) b) self-report symptom severity will be assessed at baseline (Visit 2), on the day after treatment (Visit 3), and at follow-up (Visits 4 and 5) c) clinician-rated symptom severity will be assessed at baseline (Visit 2) and at follow-up (Visits 4 and 5) d) stress test ratings will be assessed at baseline (Visit 2), on the day after treatment (Visit 3), and at follow-up (Visits 4 and 5)
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 11 |
E.8.9.1 | In the Member State concerned days | 30 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 11 |
E.8.9.2 | In all countries concerned by the trial days | 30 |